https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-platform-cas-and-novartis/ AllScien 2026-09-30T14:22:20.311786Z Novartis and CAS build reaction-data backbone for AI drug discovery https://allsci.com/news/biotech/barda-funding-antifungal-awards-scynexis-up-to/ AllScien 2026-09-30T14:05:10.461054Z Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 https://allsci.com/news/clinical-trials/retatrutide-weight-loss-diabetes-lillys-achieves/ AllScien 2026-09-30T12:24:26.614108Z Lilly’s retatrutide delivers 20.8% weight loss in Phase III diabetes-obesity trial https://allsci.com/news/clinical-trials/tasimelteon-delayed-sleep-wake-phase-disorder/ AllScien 2026-09-30T12:13:56.338062Z Vanda’s tasimelteon advances sleep timing in Phase III delayed sleep-wake disorder trial https://allsci.com/news/biotech/vvd-214-colorectal-cancer-msi-high-achieves/ AllScien 2026-09-30T11:13:04.392957Z Vividion’s WRN inhibitor shows first clinical proof of synthetic lethality in MSI-high cancers https://allsci.com/news/biotech/fenebrutinib-fda-approval-ms-accepts-roches/ AllScien 2026-09-30T10:54:54.090984Z Roche’s fenebrutinib gets FDA priority review for RMS and PPMS https://allsci.com/news/biotech/anacardio-series-b-funding-heart-failure/ AllScien 2026-09-30T09:52:19.997567Z AnaCardio raises EUR 62.5m to push ghrelin agonist AC01 toward Phase III https://allsci.com/news/biotech/tau-inhibitors-alzheimers-disease-jillion/ AllScien 2026-09-30T09:28:50.613729Z NIH backs Jillion’s oral small-molecule tau program with USD 1.12m award https://allsci.com/news/venture-financing/rna-therapeutics-funding-4bio-capital-leads-eur/ AllScien 2026-09-30T09:07:19.628187Z 4BIO Capital leads EUR 40m seed round for Aptadir's gene-reactivating RNA platform https://allsci.com/news/biotech/immix-biopharma-funding-car-t-raises-usd-125m-to/ AllScien 2026-09-30T09:00:35.536007Z Immix Bio offering to raise USD 125m after 89% CR rate for BCMA CAR T in amyloidosis https://allsci.com/news/biotech/allogeneic-car-t-cell-rejection-ut-md-anderson/ AllScien 2026-09-30T08:40:56.360501Z MD Anderson study identifies two mechanisms shaping allogeneic CAR T success https://allsci.com/news/biotech/ai3bio-series-a-funding-th17-launches-with-usd/ AllScien 2026-09-29T17:00:37.391504Z ai3Bio launches with USD 48m in Series A funding for Th17 cell targeting therapies https://allsci.com/news/corporate-strategy/ai-health-lab-ortet-launches-as-frontier-with-usd/ AllScien 2026-09-29T16:50:11.632687Z Ortet launches as frontier AI health lab with USD 500m commitment from Thoreau https://allsci.com/news/biotech/savolitinib-fda-approval-astrazeneca-seeks-for/ AllScien 2026-09-29T16:41:32.389845Z AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer https://allsci.com/news/biotech/kras-egfr-conjugate-therapy-hutchmed-launches/ AllScien 2026-09-29T15:52:36.104674Z HutchMed puts GSK-partnered KRAS-EGFR conjugate into Phase I in China https://allsci.com/news/biotech/diabetic-retinopathy-treatment-funding-breye/ AllScien 2026-09-29T15:20:13.061246Z Novo Holdings co-leads EUR 67.5m Breye Series A for danegaptide Phase II https://allsci.com/news/licensing-and-partnerships/glp-1-gip-agonist-oral-novo-nordisk-licenses/ AllScien 2026-09-29T14:15:57.365185Z Novo puts up USD 300m for Hengrui's Phase I once-weekly oral GLP-1/GIP agonist https://allsci.com/news/biotech/astrazeneca-summit-investment-ivonescimab/ AllScien 2026-09-29T14:02:00.727605Z AstraZeneca invests USD 2b in Summit to advance ivonescimab-ADC combination trials https://allsci.com/news/biotech/hpk1-protac-degrader-arvinas-enters/ AllScien 2026-09-29T13:09:25.497640Z Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial https://allsci.com/news/biotech/zenkuda-aflibercept-wamd-achieves-non-inferiority/ AllScien 2026-09-29T13:01:19.450121Z Kodiak’s Zenkuda and tabirafusp-ted meet Phase III endpoints in wet AMD https://allsci.com/news/biotech/car-t-myeloma-response-iaso-bios-dual-targeted/ AllScien 2026-09-29T12:48:04.646120Z IASO Bio’s BCMA/GPRC5D dual-targeted CAR-T RD140 shows 88.9% response rate in Phase I https://allsci.com/news/regulatory-designations-pathways/fda-breakthrough-therapy-designation-grants-to/ AllScien 2026-09-29T12:39:52.997259Z Alume wins FDA Breakthrough Therapy Designation for nerve-visualization agent bevonescein https://allsci.com/news/biotech/nts231-fda-ind-clearance-nutshell-therapeutics/ AllScien 2026-09-29T12:32:46.613091Z Nutshell Therapeutics wins FDA IND clearance for NRF2 degrader NTS231 https://allsci.com/news/biotech/prula-cel-lupus-nephritis-achieves-50-complete/ AllScien 2026-09-29T12:26:16.263095Z Adicet’s prula-cel shows 50% complete renal response rate in Phase I lupus nephritis study https://allsci.com/news/licensing-and-partnerships/lerodalcibep-licensing-agreement-sun-pharma-gains/ AllScien 2026-09-29T11:50:07.027969Z Sun Pharma gains ex-US, ex-China rights to LIB's PCSK9 inhibitor lerodalcibep https://allsci.com/news/licensing-and-partnerships/oral-glp-1-commercialization-mindrank-partners/ AllScien 2026-09-29T10:40:01.066320Z MindRank partners with 3SBio subsidiaries to commercialize AI-designed oral GLP-1 in China https://allsci.com/news/biotech/emugrobart-sma-development-chugai-resurrects-for/ AllScien 2026-09-29T09:41:48.143852Z Chugai resurrects emugrobart in SMA after Roche exits following obesity failure https://allsci.com/news/biotech/brelovitug-phase-iii-hepatitis-delta-mirums-meets/ AllScien 2026-09-28T18:04:22.014829Z Mirum's brelovitug aces Phase III in chronic hepatitis delta virus with 56% response rate https://allsci.com/news/biotech/sirna-therapeutics-rare-diseases-adarx-advances/ AllScien 2026-09-28T17:53:18.768008Z ADARx raises USD 446m in upsized Nasdaq IPO https://allsci.com/news/clinical-trials/carvykti-myeloma-remission-sustains-five-year/ AllScien 2026-09-28T17:42:19.581821Z Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients https://allsci.com/news/licensing-and-partnerships/roche-atavistik-bio-partnership-with-on/ AllScien 2026-09-28T17:37:38.129307Z Roche taps Atavistik Bio in USD 1.9bn allosteric drug discovery deal https://allsci.com/news/licensing-and-partnerships/anti-il-33-antibody-license-tolerance-bio-expands/ AllScien 2026-09-28T17:16:26.709242Z Tolerance Bio adds to thymus pipeline with anti-IL-33 antibody license from Tanabe https://allsci.com/news/biotech/kras-g12d-inhibitor-merck-acquires-preclinical/ AllScien 2026-09-28T17:08:48.755721Z Merck strikes USD 2.13bn deal for China-origin preclinical KRAS G12D inhibitor https://allsci.com/news/biotech/imfinzi-enfortumab-bladder-cancer-fda-grants/ AllScien 2026-09-28T16:42:17.346825Z AstraZeneca wins Priority Review for Imfinzi-EV regimen in bladder cancer https://allsci.com/news/approvals/juvmo-parkinsons-disease-fda-approval-approves/ AllScien 2026-09-28T16:20:41.520153Z AbbVie lands FDA approval for Cerevel-origin Parkinson’s drug Juvmo https://allsci.com/news/biotech/aav-gene-therapy-mucolipidosis-type-iv-umass-chan/ AllScien 2026-09-28T16:19:35.350800Z UMass Chan, Mass General Brigham advance first gene therapy trial in mucolipidosis type IV https://allsci.com/news/biotech/trkb-potentiator-depression-kasvu-therapeutics/ AllScien 2026-09-28T16:03:34.539603Z Finland's Kasvu secures EUR 30m Series A for non-hallucinogenic depression drug https://allsci.com/news/approvals/atebrioz-fda-approval-approves-first-oral-alk2/ AllScien 2026-09-28T15:54:52.933382Z Incyte/Mirum take FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva https://allsci.com/news/biotech/fda-clinical-hold-evenamide-stalls-newrons-us/ AllScien 2026-09-28T15:47:22.256921Z FDA keeps Newron’s ENIGMA-TRS 2 study on clinical hold https://allsci.com/news/biotech/hbv-epigenetic-silencer-therapy-nchroma-bios/ AllScien 2026-09-28T15:22:08.178707Z nChroma Bio's epigenetic silencer therapy shows sustained HBV suppression in preclinical models